Jove
Visualize
Contact Us

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiopathic peripheral neuropathy responsive to sympathetic nerve blockade and oral clonidine.

Case reports in anesthesiology·2012
Same author

Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome.

Pain practice : the official journal of World Institute of Pain·2012
Same author

Insomnia in special populations: effects of aging, menopause, chronic pain, and depression.

Postgraduate medicine·2009
Same author

Insomnia in primary care: panel discussion.

Postgraduate medicine·2009
Same author

Multivariate analysis of chronic pain patients undergoing lidocaine infusions: increasing pain severity and advancing age predict likelihood of clinically meaningful analgesia.

The Clinical journal of pain·2007
Same author

A vaccine to prevent herpes zoster.

The New England journal of medicine·2005
Same journal

Analysis of the Effectiveness of Injection-Based Minimally Invasive Treatment for Piriformis Syndrome: Clinical Outcomes and Anatomical Correlates.

Current pain and headache reports·2026
Same journal

A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Epidural Regenerative Medicine Therapies in Managing Spinal Pain.

Current pain and headache reports·2026
Same journal

Artificial Intelligence in Neuropathic Pain: From Mechanisms to Neuromodulation and Regenerative Strategies.

Current pain and headache reports·2026
Same journal

Proposed Conditions for Pain Reprocessing Therapy Readiness: Beyond Phenotyping Neuroplastic Pain.

Current pain and headache reports·2026
Same journal

Treatment of Headache in Children and Adolescents with POTS.

Current pain and headache reports·2026
Same journal

Pediatric Headache in the Age of Social Media: A Topical Review.

Current pain and headache reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
08:05

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat

Published on: November 21, 2025

Neurolytic blocks revisited.

Tracy P Jackson1, Raymond Gaeta

  • 1Stanford University School of Medicine, 780 Welch Road, Suite 280D, Palo Alto, CA 94304, USA. tracypjackson@hotmail.com

Current Pain and Headache Reports
|April 18, 2008
PubMed
Summary
This summary is machine-generated.

Neurolytic blockade offers short-term cancer pain relief, but evidence for chronic benign pain is limited. Careful patient selection and multidisciplinary management are crucial for neurolysis in non-cancer chronic pain.

More Related Videos

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
10:58

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

Related Experiment Videos

Last Updated: Jul 5, 2026

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
08:05

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat

Published on: November 21, 2025

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
10:58

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

Area of Science:

  • Pain Management
  • Interventional Pain Medicine
  • Oncology

Background:

  • Neurolytic blockade is a common treatment for cancer pain.
  • Existing data on neurolysis for chronic pain lack consistency in patient selection, diagnostic criteria, technical standards, and outcome measures.
  • No single neurolytic agent or technique has demonstrated superiority.

Purpose of the Study:

  • To review the current evidence on neurolytic blockade for cancer and chronic benign pain.
  • To highlight inconsistencies in neurolysis research and guide clinical decision-making.

Main Methods:

  • Review of existing literature on neurolytic blockade for cancer and chronic benign pain.
  • Analysis of data regarding patient selection, techniques, and outcomes.

Main Results:

  • Neurolytic techniques may benefit patients with malignant pain, offering short-term relief that can outweigh risks at end of life.
  • Limited evidence supports the long-term efficacy and low-risk application of neurolysis for chronic benign pain.

Conclusions:

  • Neurolytic blockade can be effective for managing cancer pain, particularly for short-term relief.
  • Neurolysis for chronic benign pain should be approached with caution, reserved for cases refractory to multidisciplinary treatments due to insufficient evidence of long-term efficacy and safety.